Summary of Study ST001849

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR001166. The data can be accessed directly via it's Project DOI: 10.21228/M80981 This work is supported by NIH grant, U2C- DK119886.


This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001849
Study TitleLongitudinal Metabolomics of Human Plasma Reveals Robust Prognostic Markers of COVID-19 Disease Severity (part I)
Study SummaryThere is an urgent need to identify which COVID-19 patients will develop life-threatening illness so that medical resources can be optimally allocated and rapid treatment can be administered early in the disease course, when clinical management is most effective. To aid in the prognostic classification of disease severity, we perform untargeted metabolomics on plasma from 339 patients, with samples collected at six longitudinal time points. Using the temporal metabolic profiles and machine learning, we build a predictive model of disease severity. We discover that a panel of metabolites measured at the time of study entry successfully determine disease severity. Through analysis of longitudinal samples, we confirm that the majority of these markers are directly related to disease progression and that their levels are restored to baseline upon disease recovery. Finally, we validate that these metabolites are also altered in a hamster model of COVID-19. Our results indicate that metabolic changes associated with COVID-19 severity can be effectively used to stratify patients and inform resource allocation during the pandemic.
Washington University in St. Louis
Last NamePatti
First NameGary
AddressMcMillen Chemistry Laboratory Washington University 1 Brookings Dr @ Throop Drive Rm 102 St. Louis, MO 63130-4899
Submit Date2021-01-29
Num Groups3
Total Subjects339
Num Males184
Num Females155
Raw Data AvailableYes
Raw Data File Type(s)mzML
Analysis Type DetailLC-MS
Release Date2021-06-30
Release Version1
Gary Patti Gary Patti application/zip

Select appropriate tab below to view additional metadata details:


Collection ID:CO001919
Collection Summary:Over the period of March to August of 2020, blood specimens of 341 individuals who presented at Barnes Jewish Hospital or Christian Hospital located in Saint Louis, Missouri, USA were collected. Inclusion criteria were a physician-ordered SARS-CoV-2 nasopharyngeal swab polymerase chain reaction (PCR) test with a positive or negative outcome, availability of gender and age information, and an age greater than 18. Informed consent was obtained from all study participants. The clinical cohort consisted of 155 female and 186 184 male participants. Out of the 341 339 patients, 274 272 were considered SARS-CoV-2 positive (COV+) and 67 were considered SARS-CoV-2 negative (COV-). Two individuals included in the COV+ group were later determined to be infected with other coronaviruses (NL63, HKu1). Samples were collected at the time of enrollment (d0) to the study, and 3, 7, 14, 28, or 84 days post study entry. Clinically relevant medical information (e.g., patient-reported symptoms, date of symptom-onset, age, race, and BMI) was collected at the time of enrollment from the subject or the medical record. Participant plasma was stored at -80°C upon collection.
Sample Type:Blood (plasma)